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This is a review on the current status of capsule endoscopy in the assessment of patients with gastrointestinal
bleeding of obscure origin after initial negative upper endoscopy and colonoscopy. Relevant information
was gathered from a Medline search of the English literature, previous review and original articles, references
cited in papers, and by checking the latest issues of appropriate journals. Based on the available evidence,
capsule endoscopy, if done early in the course of investigation, can identify a bleeding lesion and thus
direct subsequent test or treatment in about 60% of patients. Consequently, resources can potentially be
saved as unnecessary investigations, blood transfusions and hospital admissions can be minimized and early
implementation of definite treatments will be possible. The best candidates for capsule endoscopy are those
with ongoing overt obscure bleeding or occult obscure bleeding. Large prospective studies are necessary
to assess the impact of capsule endoscopy on clinical outcome. [Asian J Surg 2008;31(2):96–9]
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Introduction
Gastrointestinal (GI) bleeding is a common cause of hos-
pitalization. In the majority of patients, the sites of bleed-
ing are within the reach of standard upper endoscopy and
colonoscopy. GI bleeding of obscure origin is defined as
bleeding of unknown origin that persists or recurs (i.e.
recurrent or persistent iron-deficiency anaemia, positive
faecal occult blood test, or visible bleeding) after a nega-
tive initial or primary endoscopy (colonoscopy and/or up-
per endoscopy). The bleeding can be overt (melaena or
haematochezia) or occult (recurrent iron deficiency anae-
mia or positive faecal occult blood testing).1 There is a lack
of data on the medical cost associated with the manage-
ment of GI bleeding of obscure origin. The median time to
diagnosis in patients with GI bleeding of obscure origin
has been estimated to be 2 years, with a range from 1 month
to 8 years.2 Prior to the identification of a bleeding source,
patients often undergo repeated diagnostic tests, blood
transfusions, and hospitalizations; this is associated with
significant economic cost and psychological burden to
patients.
The small intestine, which is a challenging area for
investigation due to its long length and inaccessibility,
appears to be the cause in 45–70% of patients with GI
bleeding of obscure origin,3 despite it generally being an
uncommon site of GI bleeding.2 Overall, angiodysplasia
followed by small bowel tumour are the most common
aetiologies.4
Capsule endoscopy
Capsule endoscope (CE), a noninvasive imaging device, was
developed to acquire photographic images of the entire
small intestine during normal peristaltic motion. It weighs
about 3.7 g and measures about 11 × 26 mm in size, small
enough to be swallowed. It is sealed in a biocompatible
material that is resistant to digestive fluid. The single-use
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capsule comprises a camera, a light source (four white light-
emitting diodes), a radio transmitter, and batteries. During
an 8-hour long recording period, the capsule captures two
images per second in a 140° field of vision and 8:1 magni-
fication, 1–30 mm depth of view and a minimum size for
detection of about 0.1 mm. Images are transmitted by ra-
diofrequency to an eight-point abdominal sensory array
taped to the patient’s abdomen and recorded on a portable
digital recorder that is worn on a belt. The images are viewed
with dedicated software after downloading to a computer
workstation.5 The capsule is swallowed after 12 hours of
fasting and is passively propelled by peristalsis through
the gastrointestinal tract. It is then naturally excreted and
discarded. The procedure is completely ambulatory. The
patient is not confined to a medical institute and is allowed
to continue daily activities.
Following the first human study by Iddan et al in May
2000,6 CE was introduced for the investigation of GI
bleeding of obscure origin. This indication provided the
clinical basis for the FDA trial performed in 2001, which
resulted in approval of the device in the US.7 It has been
commercially available in Europe and the United States
since 2001. The key advantages of CE include ability to
review and share images, patient comfort, safety profile,
ability to conduct the procedure in a variety of settings,
clarity of image comparable to other forms of endoscopy,
and ability to image the entire small bowel.8
CE in GI bleeding of obscure origin
The diagnostic yield of CE for suspected bleeding source
in GI bleeding of obscure origin has been reported to be
55–81%.9–18 This wide range resulted from differences in
patient selection, quality of pre-CE endoscopic investiga-
tion, and non-standardized interpretation of certain CE
images.19 A consensus on the role of CE for GI bleeding
of obscure origin was reached at the 2005 International
Conference on CE (ICCE). It recommended that CE be the
preferred test for mucosal imaging of the entire small
intestine and should be part of the initial investigation.8
Intraoperative enteroscopy (IOE) is considered as the
most invasive procedure. It is usually followed by pro-
longed ileus. Its diagnostic yield ranged from 70% to 100%
in patients with GI bleeding of obscure origin.4 With IOE
considered as the criterion standard for small bowel imag-
ing for patients with GI bleeding of obscure origin, a pro-
spective two-centre study comparing IOE with CE was done.
It showed that CE was an effective method with respect to
its high sensitivity, specificity, positive and negative pre-
dictive values of 95%, 75%, 95% and 86%, respectively.20
In various comparative studies, the diagnostic yield of
CE was consistently superior to that of other investiga-
tions. While push enteroscopy is considered an effective
diagnostic procedure, it is time-consuming and only
allows exploration of the jejunum up to 160 cm distal to
the ligament of Treitz. The first comparative study be-
tween CE and push enteroscopy was performed in a canine
model. It demonstrated that CE detected more abnormal-
ities (beads sewn into the small intestine) than push en-
teroscopy.21 A subsequent pilot study comparing CE with
push enteroscopy in 40 patients with suspected small
bowel bleeding reported a higher, though not significant,
diagnostic yield with CE. It demonstrated that CE pro-
vided excellent visualization of the small bowel and it was
safe and well tolerated by patient.10 The first prospective
controlled trial comparing the two investigations was
published in 2002. CE had a significantly higher diagnos-
tic yield and detected a bleeding source in 66% of patients
versus 28% by push enteroscopy.13 A recent meta-analysis
was performed on 14 prospective studies that compared
CE with push enteroscopy. The yield of clinically signifi-
cant findings was 56% for CE versus 26% for push en-
teroscopy. CE has an incremental yield (IY) of 30%
(p < 0.00001; 95% CI, 21–38%) and the number needed to
test (NNT) for an additional clinically significant finding
was 3 (95% CI, 2–4).22 The higher diagnostic yield of CE
was mainly due to lesions found beyond the reach of push
enteroscopy.
Radiographic techniques for evaluation of small bowel
are usually unhelpful due to multiple overlapping small
bowel loops and are relatively insensitive for subtle mucosal
ulcers and angioectasias.23 Meta-analysis of three trials
that compared CE with small bowel barium radiography
(small bowel follow-through or enteroclysis) showed that
the yield of clinically significant findings was 42% versus
6%, respectively. CE has an IY of 36% (p < 0.00001; 95% CI,
25–48%) and the NNT was three (95% CI, 2–4).22
CE also established a diagnosis more often than com-
puted tomography enteroclysis (4 vs. 1) in eight patients
with GI bleeding of obscure origin.24 The diagnostic yield
of CE and magnetic resonance (MR) enteroclysis was
compared in a study of 14 patients with GI bleeding of
obscure origin. CE detected a lesion in five (36%) patients
comparing with none (0%) by MR enteroclysis.25
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Timing for CE
It has been shown that the closer the CE examination is
to the bleeding episode, the higher the diagnostic yield.
Pennazio et al11 studied 100 consecutive patients with GI
bleeding of obscure origin. The diagnostic yield of CE was
92.3% in patients with ongoing obscure overt bleeding
but 12.9% and 44.2% in those with previous obscure overt
bleeding and obscure occult bleeding, respectively.11
Lewis and Goldfarb suggested that CE should be the 
first-line method for evaluation of patients with obscure
bleeding, once upper endoscopy and colonoscopy have
been shown to be negative.2 It was suggested that CE 
done early in the course of workup of patients with GI
bleeding of obscure origin (immediately after a negative
upper and lower GI endoscopy) could considerably shorten
the time to diagnosis, lead to definitive treatment, and
avoid a number of alternative investigations with low
diagnostic yield.11
Impact on patient management
Since the initial studies on CE focused mainly on its diag-
nostic yield, there is a lack of studies reporting the clinical
outcome of patients with positive findings by CE. There-
fore, the true value of CE remains unvalidated. The study
by Pennazio et al reported a complete resolution of bleed-
ing in 86.9%, 69.2% and 41.4% of patients with ongoing
obscure overt bleeding, obscure occult bleeding and pre-
vious obscure overt bleeding, respectively. This was achieved
by subsequent definitive endoscopic or surgical treatment.11
Despite that, large prospective studies will be necessary to
assess the actual impact of CE on patient outcome. This
will not be possible without a standardized treatment
protocol with respect to specific CE findings.
Limitations of CE
The main disadvantage of CE is the inability to definitively
localize or treat the small bowel lesion detected. Biopsy
cannot be taken during the procedure. Computed tomog-
raphy and radiographic study play a role when there is 
difficulty in localizing the lesion detected by CE. Subse-
quent push enteroscopy, double balloon enteroscopy, or
surgery is required for tissue diagnosis. Furthermore, CE
is contraindicated in patients with known bowel stricture,
GI motility disorder, cardiac pacemaker, or implanted
electromechanical devices. In a retrospective review of 733
CE examinations performed in four large referral centres,
clinical problems (e.g. difficulty in swallowing the cap-
sule, incomplete small bowel examination) occurred in
16.4% of CE and diagnosis was hampered in 6.4% of
patients.26 Lesions can also be missed by CE due to rapid or
delayed small bowel transit, orientation of the camera away
from the lesion, poor bowel preparation, or perceptual
error.27 Based on the available evidence, bowel prepara-
tion and prokinetic agents might improve the quality of
small bowel cleanliness but there were insufficient data to
come to any conclusion on their effect on the completeness
of small bowel examination.28
Capsule retention rate of 0.75–1.9% has been reported
despite some patients having normal findings on radio-
graphic examinations before CE. Surgical or endoscopic
retrieval was required.26,29 The patency capsule, which is a
disintegration time-controlled capsule, was developed
recently to identify patients susceptible to capsule reten-
tion due to bowel stricture. About 40–100 hours after in-
gestion, when sufficient fluid has entered the bowel, the
capsule starts to disintegrate into small fragments. Its
persistence inside the body can be detected by a radiofre-
quency scanner.30 In addition, the actual clinical relevance
and standard criteria in the interpretation of many CE
findings remain to be investigated.
Conclusion
CE is an emerging technology with expanding evidence
confirming its role in detecting GI bleeding of obscure
origin. It is a safe, effective and well-accepted procedure.
It has a superior diagnostic yield compared with conven-
tional imaging modalities. The best candidates for CE are
those with ongoing overt obscure bleeding or occult ob-
scure bleeding. If done early in the course of investigation,
CE can potentially improve patient outcome by allowing
early diagnosis and implementation of definite treat-
ment. However, large prospective studies are necessary to
better assess the impact of CE on clinical outcome. Unlike
conventional endoscopy, CE is only diagnostic at present.
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